While the volume of regulatory data is above this point last year by more than 17%, the proportion of COVID-19-related news is nearly the same, as is the number of U.S.-approved new molecular entities (NMEs).
A look at the COVID-19 cases and deaths globally and on a weekly basis suggest that the world is not doing any better than it was this time last year, even though numerous vaccines are now authorized and approved.
A fully approved COVID-19 vaccine, clinical advances of pandemic antibodies and multibillion-dollar deals appear to be the driving forces of increasing biopharma stock prices. BioWorld’s Biopharmaceutical Index is tracking ahead by 10.6% this year, after several months of negative numbers.
Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall.
RSS
